43 results about "Mouse Mammary Gland" patented technology

The invention relates to application of chemical drugs in the field of medicine, in particular to application of glycocholic acid in preparation of antitumor drugs. The novel applicable field of glycocholic acid is provided herein; glycocholic acid is applicable to the preparation of antitumor drugs, mainly for breast cancer, ovarian cancer, endometrial carcinoma, lung cancer or their combinations; as an effective active ingredient to antitumor drugs, glycocholic acid has effective treatment quantity of 4T1 (mouse breast cancer cells) under 0.4-1.6 nmol/L, and MCF-7 (human breast cancer cells), NIH OVCAR-3 (human ovarian carcinoma cells), RL95-2 (human endometrial cancer cells), and HCC827 (human non-small cell lung cancer cells) under 16-128 mu mol/L. The application is helpful for the development of novel antitumor drugs.

The invention relates to a use of an miR-100 inhibitor in cancer metastasis reduction, and concretely relates to a use of a reagent for determining the miR-100 expression level in the preparation of breast cancer diagnosis reagents, and a use of the miR-100 inhibitor, and a use of the miR-100 inhibitor or an miR-100 antagonist in the preparation of medicines for treating breast cancer. Up-regulation of miR-100 in in-vivo tumor related macrophages and in-vitro induced M2 type macrophages is induced by tumor micro-environment. In in-vivo test, the microRNA antagonist knocks down the expression of the miR-100 in mouse mammary gland tumor tissues, and a case that in-situ tumor growth has no statistic difference, the quantity of lung metastasis tubercles is obviously down-regulated and the mammary gland tumor metastasis is inhibited in an experiment group of the miR-100 down-regulation in the tumor related macrophages is found.

The invention relates to the technical field of antineoplastic drugs, and in particular discloses application of combination of a TLR7 agonist and a tyrosine kinase inhibitor in preparing the antineoplastic drugs. The TLR7 agonist has a structure as shown in formula (I); and the tyrosine kinase inhibitor, which is lapatinib, has a structure as shown in formula (II). According to embodiments, experimental results show that the TLR7 agonist, in combination with the lapatinib, shows a significant synergistic treatment effect on treating a model of mice mammary cancer.

The invention discloses a composition with a Staphylococcus aureus resisting effect. The composition consists of general flavone of sophora flavescens and general flavone of liquorice. The general flavone parts of sophora flavescens and liquorice are prepared through extraction, extraction, enrichment and the like, and are compounded. The results of in-vitro research shows that the composition directly inhibits the growth of gram-positive bacteria such as Staphylococcus aureus and can reduce the formation of biofilms and the content of staphyloxanthin; the results of in-vivo studies prove thatthe composition can obviously reduce mammary gland alveolar hyperplasia and alveolar inflammatory cell infiltration of mice caused by Staphylococcus aureus infections, and significantly reduce the bacterium carrying amount of mouse mammary gland tissues of each model group and the content of IL-1 beta, IL-2 and TNF-alpha inflammatory factors in the mammary gland tissues. According to the invention, the comprehensive utilization of medicinal materials including sophora flavescens and liquorice and the quality and efficiency improvement of the industry can be realized; the waste is turned intothe wealth; and the composition has good economic effects and social benefits, and accords with the sustainable development strategy in China.

The invention discloses a mouse mammary gland syringe needle and application thereof. The mammary gland syringe needle is prepared by performing hot stretch deformation on a head portion of a pipettor tip and truncating a fine tubular structure formed by the stretching portion. Materials of the prepared mammary gland syringe needle are easily available, the injection effect is ideal, research materials can be provided for mammary gland pathology research. Compared with a traditional injection method that easily causes mammary gland mechanical damage or needs an expensive micro-syringe, the mouse mammary gland syringe needle has wider application value.

The invention discloses an experimental method for promoting animal mammary gland development by using vitamin B3. The method includes the following steps: S1, selecting 20 pregnant female mice, performing single culture, performing 12h:12h day and night discontinuous lighting, and performing free feeding and drinking; S2, taking care born mice by mother mice for four weeks after pregnant mice delivery, performing artificial weaning on the mice, and dividing the mice into two groups including a NT group (10) and a vitamin B3 group (10), wherein the feeding conditions of the NT group remain unchanged, and 0.5% of the vitamin B3 is added into daily feed of the vitamin B3 group; and S3, after the mice are fed for three weeks, killing the mice by cervical dislocation, and taking fourth pairs of mammary glands of the mice for Whole mount staining. According to the method for promoting the adolescent mammary gland development by using the vitamin B3, through in-vivo and in-vitro experiments,the proliferation and cyclin expression of EPH4EV cells and mouse mammary glands are detected, the molecular biology is used to comprehensively evaluate the effects of the vitamin B3 on the EPH4EV proliferation and mouse mammary gland development, and results show that the vitamin B3 can significantly promote the expression of cell proliferation markers in the cells and mouse mammary glands, thereby promoting the cell proliferation and mammary gland development.

The invention discloses a traditional Chinese medicine ointment for treating mastitis. The traditional Chinese medicine ointment comprises the following raw materials in parts by weight: 4g of menthol, 50g of herba violae, 50g of herba taraxaci and 2g of borneol. According to the application and the method of the traditional Chinese medicine ointment for treating the mastitis, a damage condition of mammary tissue is evaluated by mammary tissue paraffin sectioning and H-E staining methods, and the activity of MPO (myeloperoxidase) of mammary tissue and the expression level of inflammatory factors in the mammary tissue are detected, which proves that the traditional Chinese medicine ointment can relieve damage to the mammary tissue of a mouse; inhibits mammary gland tissue inflammatory cell infiltration and inflammatory factor expression and relieves the atrophy of mammary gland acinus, thereby effectively showing that the traditional Chinese medicine ointment can relieve the inflammatory reaction of mammary gland and has a good treatment effect on LPS-induced mouse mastitis.

The invention relates to DNA based on FAPalpha and survivin and application of the DNA based on the FAPalpha and the survivin in production of a tumor vaccine, in particular to a fused sequence, whichcan be secreted and expressed, shown in SEQ ID NO: 1 as shown in the description of an FAPalpha segment and a survivin segment and application of a DNA vaccine constructed on the basis of the sequence shown in SEQ ID NO: 1 as shown in the description in production of a therapeutic tumor vaccine, and belongs to the field of tumor DNA vaccines. According to the fused sequence, which can be secretedand expressed, shown in SEQ ID NO: 1 as shown in the description of the FAPalpha segment and the survivin segment and application of the DNA vaccine constructed on the basis of the sequence shown inSEQ ID NO: 1 as shown in the description in production of the therapeutic tumor vaccine, through an anti-tumor experiment, it is determined that compared with an individual FAPalpha vaccine and an individual survivin vaccine, the DNA vaccine has higher anti-tumor activity, and shows excellent anti-tumor effects on a mice breast cancer model and a mice pancreatic cancer model, so that the sequenceshown in SEQ ID NO: 1 as shown in the description has better application prospects in production of various tumor vaccines.

The invention discloses application of oleic acid in animal mammary gland development promotion and provides new application of the oleic acid. Cell experiments and animal experiments prove that the oleic acid can effectively promote the proliferation of pig primary mammary gland epithelial cells and mouse mammary gland epithelial cells HC11 and can increase the number of in-vivo mouse mammary gland duct branches and TEB to promote animal mammary gland development. The application has the advantages that the oleic acid is rich in source, free of substances harmful to animals and human being, safe and easy to obtain; in addition, the adding amount of the oleic acid in the application is low, and the oleic acid serving as the nutrition regulation substance can be directly added into animal feed, food or drugs and is safe, effective, free of toxic and side effects and promising in popularization and application prospect in the animal mammary gland development promotion.

The invention provides a method for overexpression of cholate activation lipase in mammary gland of a mammal. The method comprises the following steps of transferring the gene coding human cholate activation lipase into the mammal so as to realize overexpression of human cholate activation lipase in the mammary gland of the mammal. According to the method, a transgenic mouse is prepared by utilizing construction of a BSSL (bile salt stimulation lipase) mammary gland specific expression vector; and human cholate activation lipase is overexpressed in the mammary gland of the mouse, the expression quantity of the human cholate activation lipase in milk of the transgenic mouse can achieve 0.38mg/ml, and the activity is 91473.94mU/ml. A premature young mouse is fed with transgenic milk of high expression cholate activation lipase, and the result shows that the survival rate of the premature young mouse is improved by 10% compared with that of the premature young mouse fed with milk of wild mouse. The method lays a foundation for producing human cholate activation lipase by utilizing a large livestock mammary gland bioreactor.

The invention relates to a plant lignan or enterolactone and PD-1/PD-L1 inhibitor combined pharmaceutical composition and application thereof, and belongs to the technical field of biological medicine. In order to solve the problem that malignant tumor patients are insensitive to immunotherapy, the invention provides a plant lignan or enterolactone and PD-1/PD-L1 inhibitor combined pharmaceutical composition which comprises an effective dose of a plant lignan preparation or an enterolactone preparation and an effective dose of a PD-1/PD-L1 inhibitor. The combined pharmaceutical composition disclosed by the invention can increase the proportion of immune cells with an anti-cancer function and inhibit immune escape of cancer cells. The proportion of CD4 and CD8 positive cells can be up-regulated through combined medication, and the effect of inhibiting growth of mouse breast cancer is superior to that of independent medication of plant lignans, enterolactone or PD-L1/PD-1 inhibitors. The invention provides an unprecedented effective auxiliary or synergistic treatment strategy for immunotherapy of malignant tumors.

The invention discloses an isolated culture and subculture method of mouse breast cancer cells and belongs to the technical field of isolated culture methods of animal cells. The method comprises the following steps: cleaning in-vitro fresh mouse breast cancer tissue fragments subjected to pretreatment, and putting the cleaned in-vitro fresh mouse breast cancer tissue fragments into a collagenase I solution for digestive treatment; after the digestive treatment, adding culture, carrying out centrifuging, and reserving a precipitate; transferring the obtained precipitate into a culture bottle, carrying out culturing in an incubator, and beginning to change the liquid for the first time after carrying out culturing for 48 hours; after the culture is finished, removing non-adherent cells to obtain target cells; and replacing the culture medium, then, culturing the target cells, and after the target cells form a cell colony, obtaining subculturable mouse breast cancer cells. Under the condition of ensuring the purity of isolated culture of the primary cells, an isolated culture of the primary cells is shortened and simplified. According to the method, a frequent liquid change mode at an early stage of primary isolated culture in the prior art is adjusted to be complete liquid change for the first time in 48 hours, so that the liquid change frequency is greatly lowered.

The invention belongs to the technical field of molecular biology, and relates to a construction method and application of a mouse mammary tissue miRNA overexpression model. A miRNA exogenous reagent-bta-16b-agomiR is injected through mammary tissue by adopting a microsyringe, a mouse is killed 48 hours after injection, RNA is extracted from the mammary tissue by using chloroform, reverse transcription is performed to obtain cDNA, and the overexpression effect of the bta-16b-agomiR and the mRNA expression levels of PGLYRP1 and PTX3 are detected by using fluorescent quantitative PCR; and the mammary tissue is subjected to HE staining and PGLYRP1 and PTX3 immunohistochemical tests. The method disclosed by the invention can be widely applied to overexpression of miRNA in the mouse mammary tissue and related research of the miRNA in living tissue, and a model basis is provided for tests of pathology mechanisms, immune mechanisms and the like of mastitis related diseases.

The invention provides a construction method and application of a breast cancer cell strain orthotopic transplantation model, and relates to the technical field of biology. According to the construction method of the breast cancer cell strain orthotopic transplantation model, firstly, a syringe is used for inserting a needle from a single-side nipple of a fifth pair of nipples of a mouse, then a breast cancer cell solution is injected into the fourth pair of nipples on the same side to the root of a rear leg of the mouse after the needle is inserted into the skin, and the breast cancer cell strain orthotopic transplantation model is constructed. According to the invention, a special subcutaneous inoculation mode is designed according to the structural characteristics of a mouse mammary tissue anatomical map, so that the non-invasive subcutaneous injection type in-situ inoculation can be realized, the accurate in-situ tumor formation can be ensured, and the success rate of the in-situ model is improved. The construction method disclosed by the invention is simple to operate, the limitation of a common inoculation mode in the current market is solved, and greater possibility is provided for large-scale and repeatable construction of the breast cancer mouse model.

The invention discloses a preparation method of an estrogen receptor positive mouse breast cancer cell strain, and the preparation method comprises the following steps: constructing an animal model, and carrying out continuous passage on cells to obtain the required cell strain. The mouse breast cancer cells are subjected to induced culture by using the preparation method, and the mouse-derived estrogen receptor positive cell strain can be stably obtained. The mouse breast cancer cell strain with positive mouse-derived estrogen receptor prepared by the preparation method can be applied to research on the molecular mechanism of estrogen-positive breast cancer and the drug resistance mechanism of estrogen-positive breast cancer to estrogen receptor antagonist. According to the estrogen receptor positive mouse breast cancer cell strain, the problem existing in tumor immunity research by commonly using an immunodeficiency mouse model or a humanized mouse model at present is solved, and the estrogen receptor positive mouse breast cancer cell strain obtained by the invention can fill the blank of estrogen receptor-alpha positive preclinical cell models and animal models; the research on tumor immunity related to the estrogen receptor is facilitated.